Crsp stock forecast 2025.

Lithium Americas stock prediction for December 2024. In the beginning at 5.79. Maximum 6.00, minimum 5.12. The averaged price 5.62. At the end of the month 5.56 dollars, change for December -4.0%. Lithium Americas stock price forecast for January 2025. In the beginning at 5.56. Maximum 6.43, minimum 5.47.

Crsp stock forecast 2025. Things To Know About Crsp stock forecast 2025.

Nov 19, 2023 · CRISPR Therapeutics Stock Up 14.6 %. NASDAQ:CRSP opened at $67.89 on Friday. The company’s 50 day moving average price is $46.64 and its 200-day moving average price is $53.09. CRISPR Therapeutics has a 52 week low of $37.55 and a 52 week high of $72.00. The stock has a market cap of $5.39 billion, a price-to-earnings ratio of -15.19 and a ... Get a real-time CRISPR Therapeutics AG (CRSP) stock price quote with breaking news, financials, statistics, charts and more.S&P 500 Forecast 2023, 2024, 2025. Microsoft stock predictions for January 2025. The forecast for beginning of January 590. Maximum value 636, while minimum 564. Averaged Microsoft stock price for month 598. Price at the end 600, change for January 1.69%.Next reporting date. February 13, 2024. EPS forecast (this quarter) -$0.20. Annual revenue (last year) $185.3M. Annual profit (last year) -$200.2M. Net profit margin.Dec 1, 2023 · According to 42 stock analysts, the average 12-month stock price forecast for Amazon stock is $170.76, which predicts an increase of 16.14%. The lowest target is $116 and the highest is $230. On average, analysts rate Amazon stock as a strong buy.

CRISPR Therapeutics (CRSP) stock forecast for 2025 Last update: November 28, 2023 (07:48) Sector: Healthcare The share price of CRISPR Therapeutics …The Upstart Holdings stock prediction for 2025 is currently $ 64.08, assuming that Upstart Holdings shares will continue growing at the average yearly rate as they did in the last 10 years. This would represent a 141.45% increase in the UPST stock price. Nikola Corp () Stock Market info Recommendations: Buy or sell Nikola stock? Wall Street Stock Market & Finance report, prediction for the future: You'll find the Nikola share forecasts, stock quote and buy / sell signals below.According to present data Nikola's NKLA shares and potentially its market environment have been in bearish cycle last 12 …

The average TDOC stock price target stood at $124.77 a share, resulting in a potential 64% upside based on the last closing price of $75.86 (as of 28 February). The highest 12-month Teladoc share price forecast was $215, while the lowest was set at $67. Right after the company announced its results for the fourth quarter of the 2021 fiscal …

TRANSAMERICA LIFEGOALSM 2025 FUND- Performance charts including intraday, historical charts and prices and keydata. Indices Commodities Currencies StocksFind real-time CRWD - CrowdStrike Holdings Inc stock quotes, company profile, news and forecasts from CNN Business.See the latest CRISPR Therapeutics AG stock price (CRSP:XNAS), related news, valuation, ... We maintain our positive outlook and fair value estimate of $119 per share. We view the stock as very ...CRISPR stock has climbed more than 40% so far this year. An important moment may be only a few months away for CRISPR Therapeutics ( CRSP -2.22%). I'm talking about the potential approval of its ...

Discover historical prices for CRSP stock on Yahoo Finance. View daily, weekly or monthly format back to when CRISPR Therapeutics AG stock was issued.

Jun 6, 2021 · For Editas Medicine stock forecast for 2031, 12 predictions are offered for each month of 2031 with average Editas Medicine stock forecast of $8.2, a high forecast of $8.21, and a low forecast of $8.19. The average Editas Medicine stock forecast 2031 represents a 4.21% increase from the last price of $7.86999988555908.

In 2025, CRSR is forecast to generate $199,868,015,215 in revenue, with the lowest revenue forecast at $199,868,015,215 and the highest revenue forecast at $199,868,015,215. ... with the highest CRSR stock price forecast at $21.00 and the lowest CRSR stock price forecast at $14.00.On average, Wall Street analysts predict. that …Nov 28, 2023 · CRISPR Therapeutics (CRSP) stock forecast for 2025 Last update: November 21, 2023 (07:48) Sector: Healthcare The share price of CRISPR Therapeutics AG (CRSP) now CRISPR Therapeutics AG 69.97 D 0.74% (0.52) What analysts predict: $87.78 52-week High/Low: $76.19 / $37.55 50/200 Day Moving Average: $46.64 / $51.55 CRSP stock has fallen 16% over the last month (twenty-one trading days), after a rise in bond yields, along with rising concerns over the spread of a newer Covid-19 variant - Omicron - led to a ...That has helped lift growth stocks as investors prepare their portfolios for better times. And one particular stock to benefit is biotech CRISPR Therapeutics (CRSP 0.92%). The stock has advanced ...NEW YORK, Jan. 14, 2020 /PRNewswire/ --The Global Sports Analytics Market size is expected to reach $4.3 billion by 2025, rising at a market growt... NEW YORK, Jan. 14, 2020 /PRNewswire/ -- The Global Sports Analytics Market size is expecte...AbCellera Biologics Inc () Stock Market info Recommendations: Buy or sell AbCellera Biologics stock? Wall Street Stock Market & Finance report, prediction for the future: You'll find the AbCellera Biologics share forecasts, stock quote and buy / sell signals below.According to present data AbCellera Biologics's ABCL shares and potentially its …

Wall Street Stock Market & Finance report, prediction for the future: You'll find the AbCellera Biologics share forecasts, stock quote and buy / sell signals below. According to present data AbCellera Biologics's ABCL shares and potentially its market environment have been in bearish cycle last 12 months (if exists).The current CRISPR Therapeutics AG [ CRSP] share price is $66.73. The Score for CRSP is 52, which is 4% above its historic median score of 50, and infers lower risk than normal. CRSP is currently trading in the 50-60% percentile range relative to its historical Stock Score levels. Oct 10, 2023 · CRISPR Therapeutics Stock Forecast 2023. In the last five quarters, CRISPR Therapeutics’s Price Target has risen from $0.00 to $40.65 - a 100% increase. One analysts predict that CRISPR Therapeutics’s share price will increase in the coming year, reaching $150.00. This would represent an increase of 269%. Be the first to know when Wall Street analysts revise their CRWD stock forecasts and price targets. Get Free CRWD Updates. CRWD stock forecasts by analyst. All ... On average, 13 Wall Street analysts forecast CRWD's revenue for 2025 to be $933,992,560,162, with the lowest CRWD revenue forecast at $920,170,065,158, and the highest CRWD revenue ...How much will CRISPR Therapeutics cost in 2021 – 2025? Forecast: (CRSP) for today November 26 & Weekly Forecast from 19 November to 2 December Price Prediction …

Wall Street Stock Market & Finance report, prediction for the future: You'll find the Editas Medicine share forecasts, stock quote and buy / sell signals below. According to present data Editas Medicine's EDIT shares and potentially its market environment have been in a bullish cycle in the last 12 months (if exists).

Wall Street Stock Market & Finance report, prediction for the future: You'll find the Rambus share forecasts, stock quote and buy / sell signals below. According to present data Rambus's RMBS shares and potentially its market environment have been in a bullish cycle in the last 12 months (if exists).The Roku Inc - Class A stock forecast is 205.24788816489 USD for 2024 November 30, Saturday; and 1033.706 USD for 2028 November 30, Thursday with technical analysis. Roku Inc - Class A (ROKU) stock price prediction is 205.24788816489 USD.With that in mind, let's look at two gene-editing-focused biotechs that could perform substantially better next year: CRISPR Therapeutics ( CRSP -6.39%) and Bluebird Bio ( BLUE -4.44%). These ...For TELADOC HEALTH INC stock forecast for 2023, 2 predictions are offered for each month of 2023 with average TELADOC HEALTH INC stock forecast of $19.58, a high forecast of $20.12, and a low forecast of $19.04. The average TELADOC HEALTH INC stock forecast 2023 represents a 4.7% increase from the last price of $18.7000007629395.Alembic Pharmaceuticals Stock Forecast, 533573 stock price prediction. Price target in 14 days: 749.727 INR. ... Alembic Pharmaceuticals Ltd Stock Price Forecast for 2025: February 2025: Open: 549.494: Close: 539.101: Min: 539.075: Max: 549.494: Change: -1.93 % Alembic Pharmaceuticals Ltd Stock Price Forecast for 2025:Stock Price Forecast. The 5 analysts offering 12-month price forecasts for Danimer Scientific Inc have a median target of 3.00, with a high estimate of 3.75 and a low estimate of 2.00. The median ...Learn More Could CRISPR Therapeutics be the next big healthcare stock? Gene-editing therapies aren't common today, but years from now that could change. One …Stock Price Forecast According to 16 stock analysts, the average 12-month stock price forecast for CRSP stock stock is $69.88, which predicts an increase of …Target values for the price of one Lithium Americas share for Nov 2025. The weighted average target price per Lithium Americas share in Nov 2025 is: 7.98. In Nov, the Positive dynamics for Momo shares will prevail with possible monthly volatility of 26.367% volatility is expected. Pessimistic target level: 6.79. Optimistic target level: 9.23.

Alembic Pharmaceuticals Stock Forecast, 533573 stock price prediction. Price target in 14 days: 749.727 INR. ... Alembic Pharmaceuticals Ltd Stock Price Forecast for 2025: February 2025: Open: 549.494: Close: 539.101: Min: 539.075: Max: 549.494: Change: -1.93 % Alembic Pharmaceuticals Ltd Stock Price Forecast for 2025:

Assuming $18 billion in free cash flow -- the low end of T-Mobile's target -- and just a 15 P/E ratio in 2025, one could see T-Mobile trading at a market cap of $270 billion, up about 75% from ...

Find the latest CRISPR Therapeutics AG CRSP analyst stock forecast, price target, and recommendation trends with in-depth analysis from research reports. Date Range …1 CRSP® is a registered trademark and service mark of Center for Research in Security Prices, LLC and has been licensed for use by D&P/Kroll. The D&P/Kroll publications and services are not sponsored, sold or promoted by CRSP®, its affiliates or its parent company. To learn more about CRSP, visit www.crsp.com. 2 Depending on subscription level. YRVLV Stock 12 Months Forecast. $14.73. (0.48% Upside) Based on 14 Wall Street analysts offering 12 month price targets for Revolve Group in the last 3 months. The average price target is $14.73 with a high forecast of $18.00 and a low forecast of $10.50. The average price target represents a 0.48% change from the last price of $14.66.InvestorPlace - Stock Market News, Stock Advice & Trading Tips There are plenty of electric vehicle (EV) startups out there to choose from. So... InvestorPlace - Stock Market News, Stock Advice & Trading Tips There are plenty of electri...According to our CRISPR Therapeutics AG stock prediction for 2025, CRSP stock will be priced at $ 114.05 in 2025. This forecast is based on the stock’s average …The CRISPR Therapeutics stock price gained 2.88% on the last trading day (Friday, 1st Dec 2023), rising from $66.73 to $68.65. During the last trading day the stock fluctuated 8.38% from a day low at $63.39 to a day high of $68.70. The price has been going up and down for this period, and there has been a 15.92% gain for the last 2 weeks.CRSP - CRISPR Therapeutics AG Stock - Stock Price, Institutional Ownership, Shareholders (NASDAQ)All stock predictions. Overall outlook for CRISPR Therapeutics stock. 2023. ... (CRSP) stock consensus forecasts for 2025. Last update: 06/17/2023, 02:26 AM Brief ...Analysts expect revenue growth at 8% this year and further acceleration above double digits through 2025. EPS growth is also at ~25 for 2024 and 2025, respectively — very attractive at these levels.SGMO Stock 12 Months Forecast. $3.09. (599.73% Upside) Based on 7 Wall Street analysts offering 12 month price targets for Sangamo Biosciences in the last 3 months. The average price target is $3.09 with a high forecast of $7.00 and a low forecast of $1.00. The average price target represents a 599.73% change from the last price of $0.44.

Price Prediction CRISPR Therapeutics price predictions from 2023 to 2027. Gain insights into monthly forecasts, trends, and analyses to make informed investment decisions.The global CRISPR gene editing market was valued at $846.2 million in 2019 and is expected to reach $10,825.1 million by 2030, registering a CAGR of 26.86% during the forecast.Apr 13, 2022 · Among the leaders in the nascent CRISPR space are biotech stocks like CRISPR Therapeutics, (CRSP 2.88%) Editas Medicine, and Intellia Therapeutics. These companies have pipelines that are jam ... See CRISPR Therapeutics AG (CRSP) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. Instagram:https://instagram. td ameritrade sweep interest rateozempic kidneyportfoliopilotstocks that dropped the most today TRANSAMERICA LIFEGOALSM 2025 FUND- Performance charts including intraday, historical charts and prices and keydata. Indices Commodities Currencies Stocks best company to buy gold bullion fromlow stock dividend CRISPR Therapeutics AG Stock Prediction 2025. The CRISPR Therapeutics AG stock prediction for 2025 is currently $ 114.05, assuming that CRISPR Therapeutics AG shares will continue growing at the average yearly rate as they did in the last 10 years. This would represent a 70.91% increase in the CRSP stock price.Despite the pain today, there are a handful of Cathie Wood stocks that could double by 2025. Here are three of them. Despite the pain today, there are a handful of intriguing Cathie Wood stocks Source: rhendrikdwenz via Shutterstock It’s be... zoomgate For Vaxart stock forecast for 2033 (10 year), 10 predictions are offered for each month of 2033 with average Vaxart stock forecast of $16.43, a high forecast of $18.46, and a low forecast of $12.03. The average Vaxart stock forecast 2033 represents a 2389.86% increase from the last price of $0.660000026226044. Please, see more forecasts below.May 19, 2023 · Cash and securities were $1.9 billion as of March 31, 2023 and net loss was only $53.1 million for Q1 2023, so there is no danger of dilution in the near future. Under the Vertex Joint Development ...